Long-acting cabotegravir injections for HIV prevention
Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)
This project looks at whether bimonthly cabotegravir injections can make HIV prevention easier and reach people who have trouble taking daily pills, especially in Black, Latino, and transgender communities.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Pilgrim Health Care, INC. NIH-funded |
| Lab location | 1 site (Canton, UNITED STATES) |
| Project ID | NIH-11369747 on NIH RePORTER |
What this research studies
You might be invited through clinics or community programs to learn about and receive long‑acting cabotegravir injections instead of daily oral PrEP. The research uses clinic data, patient surveys, and follow-up visits to track who starts and stays on injections, what barriers they face, and how monitoring strategies like oral ramp‑down or extra viral testing affect safety. The team focuses on groups at higher risk of HIV and underrepresented among current PrEP users to find fair ways to expand access. Findings will inform practical clinic approaches to reduce infections, inequities, and drug resistance risks.
Who could benefit from this research
Good fit: People at substantial risk for HIV—including men who have sex with men, transgender women, and cisgender women, especially Black and Latino individuals who have difficulty taking daily pills—are most likely to be eligible.
Not a fit: People who already have HIV, have medical contraindications to cabotegravir, or cannot attend regular injection visits may not benefit from this intervention.
Why it matters
Potential benefit: If successful, this work could make HIV prevention simpler for people who struggle with daily pills and help reduce racial and gender gaps in PrEP access.
How similar studies have performed: Large clinical trials have already shown that long‑acting cabotegravir injections can prevent HIV better than daily oral PrEP, but real‑world implementation, equity, and resistance questions remain less studied.
Where this research is happening
Canton, UNITED STATES
- Harvard Pilgrim Health Care, INC. — Canton, United States (Active)
Researchers
- Principal investigator: Marcus, Julia L. — Harvard Pilgrim Health Care, INC.
- Study coordinator: Marcus, Julia L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.